NiSCELL is a Malaysian Biotechnology Company incorporated in 2007 to principally engage in laboratory research on cell based products and developing immunotherapy for cancer and stem cell therapy for regenerative diseases. NiSCELL’s technology originated from Japan. Besides being a Bionexus Status company, NiSCELL in 2009 was accredited with GMP (Good Manufacturing Practice) status certified by National Pharmaceutical Regulatory Agency (NPRA) and blood bank licensed by the Ministry of Health Malaysia.
NiSCELL provides a platform for collaborators where there is a potential for cell-based therapy for regenerative disorders.
NiSCELL core strength is to manufacture human peripheral blood derived Natural Killer (NK) Cells, Cytotoxic T Lymphocytes (CTL) and Umbilical Cord-derived allogenic Mesenchymal Stem Cells (MSCs) in order to facilitate their effective use in basic and translational research as well as for future clinical applications.
Our live cell-based products are manufactured in our own cGMP compliant facility and handled by high profile scientists. These products are being pre-clinically investigated for frailty and various cancer treatments.
Our core strength is possession of technology and materials, all patented for isolation, processing, expansion and preservation of clinically usable stem cells, progenitor cells, precursor cells as well as mature cells. We are committed to the highest international standards for ethics and scientific values.
NiSCELL will focus on providing facilities to Hospitals and Doctors to Regenerate health with Immunotherapy and Stem Cells.